The high sensitivity toward PLK1 inhibitors in MPNST as compared to other cancer cell lines may at least in part be linked to the increased RAS signaling due to the loss of tumor suppressor NF1. This is supported by studies of colon cancer models showing increased sensitivity toward PLK1 inhibition in KRAS‐mutated cells (Luo et al., 2009; Wang et al., 2016). This evidence concerns the gene KRAS and neoplasm.